Artivion (AORT) Stock Price, News & Analysis

Company Overview

Artivion, Inc. (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation. Headquartered in Kennesaw, Georgia, Artivion operates manufacturing and processing facilities in the United States and Europe, with commercial teams serving hospitals and surgical centers across North America, Latin America, Europe, the Middle East and Asia-Pacific. Its global footprint is supported by direct sales operations and distribution partnerships that deliver both off-the-shelf and custom tissue solutions to clinicians worldwide.

Leadership at Artivion is focused on expanding the company’s product pipeline through research and development initiatives and strategic acquisitions. Under the direction of CEO Paul F. Le Gars, the company has pursued regulatory approvals across multiple markets and invested in next-generation tissue processing technologies. Through this combination of biologic innovation and device engineering, Artivion aims to address unmet clinical needs in cardiovascular surgery and improve patient outcomes over the long term.

Key Stats

• Today's Range: $40.33 to $40.97
• 50-Day Range: $30.46 to $44.81
• 52-Week Range: $21.97 to $45.07
• Volume: 79,724 shs
• Average Volume: 445,786 shs
• Market Capitalization: $1.93 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.63
• Consensus Rating: Buy

Artivion Stock Analysis - MarketRank™

Artivion scored higher than 52% of companies evaluated by MarketBeat, and ranked 535th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Artivion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Upside/Downside

The consensus price target for Artivion is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Artivion has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 35.14%

Earnings Growth

Earnings for Artivion are expected to grow by 35.14% in the coming year, from $0.37 to $0.50 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Artivion is -97.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Artivion is -97.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Artivion has a P/B Ratio of 6.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.48% of the float of Artivion has been sold short.

Short Interest Ratio / Days to Cover

Artivion has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Artivion has recently increased by 9.45%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Artivion does not currently pay a dividend.

Dividend Growth

Artivion does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.48% of the float of Artivion has been sold short.

Short Interest Ratio / Days to Cover

Artivion has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Artivion has recently increased by 9.45%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 1.44

News Sentiment

Artivion has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Artivion this week, compared to 4 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,250,129.00 in company stock.

Percentage Held by Insiders

Only 8.10% of the stock of Artivion is held by insiders.

Percentage Held by Institutions

86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AORT Stock Analysis - Frequently Asked Questions

How have AORT shares performed this year?

Artivion's stock was trading at $28.59 at the beginning of 2025. Since then, AORT shares have increased by 43.0% and is now trading at $40.8910.

How were Artivion's earnings last quarter?

Artivion, Inc. (NYSE:AORT) issued its quarterly earnings data on Thursday, August, 7th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.13. The business's quarterly revenue was up 15.3% compared to the same quarter last year.
Read the conference call transcript.

Who are Artivion's major shareholders?

Artivion's top institutional shareholders include Next Century Growth Investors LLC (2.13%), Geode Capital Management LLC (2.07%), Bank of America Corp DE (1.37%) and Ophir Asset Management Pty Ltd (1.31%). Insiders that own company stock include James P Mackin, David Ashley Lee, John E Davis, Jean F Holloway, Amy Horton, Lance A Berry, Marshall S Stanton, Rochelle L Maney, Dennis B Maier, Matthew A Getz, Andrew M Green and Anthony B Semedo.
View institutional ownership trends.

How do I buy shares of Artivion?

Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Artivion own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Artivion investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/22/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:AORT
• CIK: 784199
• Web: www.cryolife.com
• Phone: (770) 419-3355
• Fax: 770-426-0031
• Employees: 1,600
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Artivion: $40.63
• High Price Target: $50.00
• Low Price Target: $32.00
• Potential Upside/Downside: +0.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 109.51
• P/E Growth: N/A
• Net Income: -$13.36 million
• Net Margins: -4.43%
• Pretax Margin: -4.12%
• Return on Equity: 5.70%
• Return on Assets: 2.29%

Debt

• Debt-to-Equity Ratio: 0.52
• Current Ratio: 4.78
• Quick Ratio: 3.48

Sales & Book Value

• Annual Sales: $388.54 million
• Price / Sales: 4.92
• Cash Flow: $0.83 per share
• Price / Cash Flow: 48.60
• Book Value: $6.59 per share
• Price / Book: 6.15

Miscellaneous

• Outstanding Shares: 47,180,000
• Free Float: 43,362,000
• Market Cap: $1.91 billion
• Optionable: Optionable
• Beta: 1.69